Status:
COMPLETED
Anesthesia and Lymphocytes Apoptosis
Lead Sponsor:
Ruijin Hospital
Conditions:
Anesthesia
Eligibility:
MALE
18-80 years
Phase:
NA
Brief Summary
Most researches revealed that volatile anesthetic sevoflurane has a more marked cardioprotective effect against ischemia compared with intravenous agent propofol.However, propofol has been suggested t...
Eligibility Criteria
Inclusion
- male adults
- aged 18-80 yr
- undergoing elective OPCAB surgery containing left anterior descending artery bypass
Exclusion
- a previous unusual response to any of the experimental anesthetics
- severe cardiac dysrhythmias or ejection fraction below 30%
- hemodynamic instability
- previous surgical coronary artery repair
- anemia, abnormal leukocytes or coagulopathy
- severe hypertension
- severe hepatic (albumin\<30g,ascites), renal (serum creatinine greater than 2.0 mg/dl) or pulmonary (preoperative pulmonary function tests moderate-severe) dysfunctions
- concomitant surgical procedures and psychiatric disorders
- Insulin-dependent diabetics
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT01461551
Start Date
October 1 2011
End Date
October 1 2014
Last Update
May 22 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin Hospital
Shanghai, Shanghai Municipality, China, 200025